Wouldn't that expenditure simply be expenditure relating to Walyering?
I would assume they are both non current assets and that its appropriate to classify the expenditure there as opposed to 2.1d - exploration and evaluation, which is probably Gurvantes XXXV.
I don't think there is any cause for concern with the classification of the expenditure.
- Forums
- ASX - By Stock
- TPD
- Colby's Response to STX Offer
Colby's Response to STX Offer, page-226
-
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TPD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online